Concepedia

Author

Matthias Karrasch

European Organisation for Research and Treatment of Cancer

Also Known As

M Karrasch, M. Karrasch, Marina Karrasch, Matthias Karrasch

74

Publications

2.4K

Citations

19

H-Index

53

Concepts

All Affiliations

European Organisation for Research and Treatment of CancerJena University HospitalMedigene (Germany)Sapienza University of RomeFondazione Gimema Onlus
MK

About

Matthias Karrasch is an author at European Organisation for Research and Treatment of Cancer specializing in medicine, oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

9

9

491

2

Health Sciences

3

3

348

3

Engineering

1

1

23

4

Diabetes

1

1

280

5

Environmental Engineering

1

1

23

Matthias Karrasch

×

24

Publications

2.2K

Citations

19

H-Index

YearCitations

Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBM

James M. Markert, Peter Liechty, Wenquan Wang,

Molecular Therapy

2008

398

A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses

James M. Markert, Shantanu N. Razdan, Hui‐Chien Kuo,

Molecular Therapy

2014

305

A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study

Christian Holubarsch, M. Rohrbach, Matthias Karrasch,

Clinical Science

2007

280

Phase I, Open-Label, Dose-Escalating Study of a Genetically Engineered Herpes Simplex Virus, NV1020, in Subjects with Metastatic Colorectal Carcinoma to the Liver

Nancy E. Kemeny, Karen T. Brown, Anne M. Covey,

Human Gene Therapy

2006

169

Vaccination trial with HPV16 L1E7 chimeric virus‐like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3)

Andreas M. Kaufmann, John D. Nieland, Ingrid Jochmus,

International Journal of Cancer

2007

134

Eight Cycles of ABVD Versus Four Cycles of BEACOPP<sub>escalated</sub>Plus Four Cycles of BEACOPP<sub>baseline</sub>in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial

Patrice Carde, Matthias Karrasch, Catherine Fortpied,

Journal of Clinical Oncology

2016

120

Prospective International Multicenter Phase II Trial of Intravenous Pegylated Liposomal Doxorubicin Monochemotherapy in Patients With Stage IIB, IVA, or IVB Advanced Mycosis Fungoides: Final Results From EORTC 21012

Reinhard Dummer, Pietro Quaglino, Jürgen C. Becker,

Journal of Clinical Oncology

2012

103

Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00

Sean Whittaker, Reinhard Dummer, Annamari Ranki,

British Journal of Dermatology

2012

93

Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17)

Sergio Amadori, Stefan Suciu, Roberto Stasi,

Journal of Clinical Oncology

2013

88

A Herpes Oncolytic Virus Can Be Delivered Via the Vasculature to Produce Biologic Changes in Human Colorectal Cancer

Yuman Fong, Teresa S. Kim, Amit Bhargava,

Molecular Therapy

2008

85

Page 1